Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

BiondVax Pharmaceuticals Ltd.. (4/30/18). "Press Release: BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update". Ness Ziona.

Organisations Organisation BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV)
  Organisation 2 National Institute of Allergy and Infectious Diseases (NIAID) (US)
  Group United States (govt)
Products Product M-001 universal flu vaccine (BiondVax)
  Product 2 clinical research
Persons Person Babecoff, Ron (BiondVax 201709 CEO)
  Person 2 Phillipson, Joshua (BiondVax 201707 Business Development Manager)
     


   
Record changed: 2018-05-09

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top